this is interesting on ownership of the drug and w

this is interesting on ownership of the drug and who is paying for the trials - that is a concern on revenue split

________________________________________

Raghuram Selvaraju, Chairman of Relief Therapeutics, comments on the newly gained billion-dollar valuation of the small Swiss biotech company and explains the approval chances for its drug Aviptadil to treat Covid-19.
- - - - - - - - - - - - - - - - - - - - - - - - - - - -

Who finances the ongoing trials?

Relief is paying for the trials. NeuroRx conducts the study on our behalf and we cover all the invoices.

Do you have an agreement with NeuroRx about who receives how much of the profits from Aviptadil? Or is the drug fully owned by Relief?

Aviptadil is our drug.

You are entitled to all revenues it could create?

That is the current situation.


https://themarket.ch/interview/relief-therape...ar-ld.2478

How much do the trials cost?

There are effectively two trials: For the one we are currently running the total budget will be in the range of CHF 7 to 8 mio. The Inhaled study we just got approval to start will probably cost between CHF 10 and 15 mio.